Right Heart Failure

Clinical Evidence


Impella RP heart pump is the most studied right-sided device and the only percutaneous technology with FDA approval designating it as safe and effective for right-heart support. Its exclusive FDA approval is a result of more than eight years of clinical studies.

RECOVER RIGHT: Safety & Efficacy

73% overall survival-to-discharge at 30 days1

All patients discharged were alive at 180 days1

Sustained hemodynamic improvement after Impella RP® heart pump support1

  • Increase in cardiac index (CI)
  • Decrease in central venous pressure (CVP)

Fewer benchmark adverse events at 30 days1 compared to other RVAD studies

  • Death, bleeding, hemolysis
  • Neurologic dysfunction and limb ischemia

National Cardiogenic Shock Initiative (NCSI) Study Findings Regarding Right Ventricular Dysfunction

Babar Basir, DO, discusses findings on right heart dysfunction from the NCSI Study.


Anderson MB, et al. J Heart Lung Transplant. 2015; 34(12):1549-1560


This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].